I read that 20% or more of purchase price, depending on the price of mylan at close, is to be funded with stock. As mylan drops in price that percentage will go up. My point is that whatever earnings the deal can add will be directly diluted by more stock and debt. Not to mention bad PR with existing stock holders. I am NOT a short and in fact have been looking for an opportunity to buy. But over and over again management has proven their vision is myopic. GLTA
As to Teva sweetening the offer, not going to happen. That idea is what kept long time mylan holders from selling at $70. I.e. they wanted $80. I do like this companies business prospects but with current management I could not buy at $45. They are in it for themselves. IMHO.
are rising. May even get to what teva paid and more. could be a significant amount to tap into. Would not rush into a huge teva share sale as we are rising too. parcel it out slowly and sell some mylan. Just my thoughts.